NeuroEM Therapeutics Inc Press Release

August 6, 2019

Today I am very proud to be part of the announcement that NeuroEM Therapeutics Inc. has made in a major press release on the results of the first human trials of Transcranical Electromagnetic Treatment (TEMT) on patients with Alzheimer’s disease (AD).

·       Results published in the Journal of Alzheimer’s Disease suggest an easy-to-wear head device from NeuroEM Therapeutics reversed memory loss in patients with mild to moderate Alzheimer’s disease.

o   The study shows that two months of in-home transcranial electromagnetic treatment (TEMT) was safe and improved memory performance.

o   After two months of treatment, memory decline in most patients appeared to have been reversed to cognitive levels equivalent to 12 months earlier.

·       Results point to potential breakthrough in AD treatment but need to be reconfirmed in a larger pivotal trial in 2020

o   Despite the best efforts of many researchers over the past 20 years, stopping or reversing memory impairment of AD has eluded them.

o   TEMT seems to provide a combination of mechanisms to attack the AD process, including disaggregation of two toxic proteins (beta-amyloid and tau) that appear to be the disease’s root causes - something the study authors believe has not been seen with other AD therapeutics that are currently in clinical development.

·       The MemorEM is an investigational, novel, non-invasive head device that delivers radio waves to the brain and is designed to be easy to wear for the patient at home.

·       AD, a progressive lethal brain disease causing memory loss and other serious symptoms, impacts an estimated 5.8 million Americans, a number projected to more than double to 14 million by 2050.

Reference to Article in Journal of Alzheimer’s Disease

1. Arendash G et al. A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer’s Disease: Cognitive Enhancement and Associated Changes in CSF, Blood and Brain Imaging. J Alzheimer Dis. 2019;71 (1),